Leitura clínica
Comentário
Derivado salicílico com propriedades anti-inflamatórias, imunossupressoras e bacteriostáticas utilizado na colite ulcerosa. Administração oral ou retal 1 a 3 vezes ao dia. A mesalazina é absorvida mal no intestino, especialmente se a administração é por via retal. Os níveis plasmáticos são muito baixos e passa em muito escassa quantidade ao leite (Datta 2019), embora um metabólito (inativo para tratar a doença), o N-acetil-5-ASA (Na5ASA), passe em maior concentração ao leite mas sem superar 10% da dose relativa (Silverman 2005, Christensen 1994, Klotz 1993, Miller 1993, Jenss 1990). Não foram descritos problemas em mais de 130 bebês que mamam de mães que a tomaram (Datta 2019, Xu 2017, Moretti 1989), salvo algum caso isolado de diarreia (Ito 1993, Nelis 1989, Branski 1986). Diversas sociedades médicas, especialistas e consensos de especialistas consideram seguro o uso desta medicação durante a amamentação (Huang 2016, Nguyen 2016, Damas 2015, van der Woude 2015, Mahadevan 2015, Schulz 2014, Nielsen 2014, Yarur 2013, Salinger 2012, Habal 2012, Van Assche 2010, van der Woude 2010, Mottet 2009, Heetun 2007, Mahadevan 2006, Connell 1996). É muito discutível (Sánchez 2004) que a trombocitose que teve um bebê de 4 meses cuja mãe estava em tratamento crônico com mesalazina, se deva à mesalazina ou à suspensão brusca da amamentação (Barriuso 2003).
Encontrabilidade
Outros nomes e marcas
Sinônimos e grafias 9
- 5-ASA
- Fisalamina
- Mesalamina
- Ácido 5-Aminosalicilico (5-ASA)
- ميزالازين
- Месалазин
- 美沙拉秦
- メサラジン
- A07EC02
Marcas comerciais na fonte 78
- Anjiesha (安洁莎)
- Apriso
- Asacol
- Asacol (Асакол)
- Asacolon
- Asalazin
- Asalex
- Asalit
- Asamax
- Asavixin
- Asazine
- Asocol
- Azzavix
- Bufexan
- Canasa
- Chron-ASA
- Claversal
- Colitan
- Colitofalk
- Conductasa (Argentina)
- Cosacol
- Crohnax
- Crohnezine
- Cronezil
- Croxalan
- Delzicol
- Ectospasmol
- Elmes
- Empenox
- Enteraproct
- Enterasin
- Enterin
- Etiasa
- Etiasa (艾迪莎)
- Exotran
- Favorat
- Fivasa
- Ipocol
- Jucolon
- Laboxantryl
- Lextrasa
- Lialda
- Lixacol
- Mecolzine
- Mesacol
- Mesacol (Месакол)
- Mesaflor
- Mesagin
- Mesagran
- Mesasal
- Mesavancol
- Mesax
- Mezavant
- Midodrine (Indonesia)
- Numalazina
- Octasa
- Pentacol
- Pentasa
- Pentasa (Пентаса)
- Pentasa (颇得斯安)
- Plimage
- Proctasacol
- Prozylex
- Quintasa
- Rectocalm
- Rowasa
- Salcrozine
- Salofalk
- Salofalk (Салофальк)
- Salofalk (莎尔福)
- Samezil (Самезил)
- Sekena
- Seramine
- Suprimal
- Xalazin
- Xalazina
- Yolecol
- Zintasa
Dados da fonte
Farmacocinética
| Variável | Valor | Unidade |
|---|---|---|
| Biodisp. oral | Rec. 10 - 30. Oral 30 - 50 | % |
| Peso Molecular | 153 | daltons |
| Unión proteínas | 40 - 55 | % |
| Vd | 0,26 | l/Kg |
| pKa | 2,02 | - |
| Tmax | 4 - 12 | horas |
| T½ | 5ASA 0,6. Na5ASA: 10 | horas |
| Índice L/P | 0,3 - 5 | - |
| Dosis Teórica | 0,02. Na5ASA: 2,7 | mg/Kg/d |
| Dosis Relativa | 0,03 - 0,06. Na5ASA: 5,4 - 7,4 | % |
Rastreabilidade
Bibliografia
- Hoxha T, Youssef M, Huang V, Tandon P. Inflammatory Bowel Disease and Breastfeeding: A Narrative Review. Inflamm Bowel Dis. 2025 Jan 6;31(1):210-219. Resumen
- Datta P, Rewers-Felkins K, Kallem RR, Baker T, Hale TW. Determination of Mesalamine levels in Human Milk as a Function of Dose. Breastfeed Med. 2019 Mar;14(2):98-101. Resumen
- Mahadevan U, Robinson C, Bernasko N, Boland B, Chambers C, Dubinsky M, Friedman S, Kane S, Manthey J, Sauberan J, Stone J, Jain R. Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. 2019 Apr;156(5):1508-1524. Resumen Texto completo (enlace a fuente original)
- AEMPS-FalkPharma. Mesalazina (Salofalk). Ficha técnica. 2017 Texto completo (en nuestros servidores)
- Xu Y, Tan B, Ma L, Song Y, Zhou X, Qi Q, Liu J Inflammatory bowel disease in pregnancy: a report of 7 cases and review of the literature. Int J Clin Exp Med 2017;10(3):5525-5532 2017 Texto completo (enlace a fuente original) Texto completo (en nuestros servidores)
- Huang VW, Chang HJ, Kroeker KI, Goodman KJ, Hegadoren KM, Dieleman LA, Fedorak RN. Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding Varies Widely: A Need for Further Education. Can J Gastroenterol Hepatol. 2016;2016:6193275. Epub 2016 Sep 20. Resumen Texto completo (enlace a fuente original) Texto completo (en nuestros servidores)
- Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, Leontiadis GI, Tse F, Mahadevan U, van der Woude CJ; IBD in Pregnancy Consensus Group. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2016 Mar;150(3):734-757.e1. Resumen Texto completo (enlace a fuente original) Texto completo (en nuestros servidores)
- McConnell RA, Mahadevan U. Pregnancy and the Patient with Inflammatory Bowel Disease: Fertility, Treatment, Delivery, and Complications. Gastroenterol Clin North Am. 2016 Resumen
- Mahadevan U, Matro R. Care of the Pregnant Patient With Inflammatory Bowel Disease. Obstet Gynecol. 2015 Aug;126(2):401-12. Resumen
- Damas OM, Deshpande AR, Avalos DJ, Abreu MT. Treating Inflammatory Bowel Disease in Pregnancy: The Issues We Face Today. J Crohns Colitis. 2015 Oct;9(10):928-36. Resumen Texto completo (enlace a fuente original) Texto completo (en nuestros servidores)
- van der Woude CJ, Ardizzone S, Bengtson MB, Fiorino G, Fraser G, Katsanos K, Kolacek S, Juillerat P, Mulders AG, Pedersen N, Selinger C, Sebastian S, Sturm A, Zelinkova Z, Magro F; European Crohn’s and Colitis Organization. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015 Feb;9(2):107-24. Review. Resumen Texto completo (enlace a fuente original) Texto completo (en nuestros servidores)
- Nielsen OH, Maxwell C, Hendel J. IBD medications during pregnancy and lactation. Nat Rev Gastroenterol Hepatol. 2014 Feb;11(2):116-27. Resumen
- Schulze H, Esters P, Dignass A. Review article: the management of Crohn's disease and ulcerative colitis during pregnancy and lactation. Aliment Pharmacol Ther. 2014 Nov;40(9):991-1008. Resumen Texto completo (enlace a fuente original) Texto completo (en nuestros servidores)
- FDA-Shire. Mesalamine(Pentasa). Drug Summary. 2013 Texto completo (en nuestros servidores)
- Yarur A, Kane SV. Update on pregnancy and breastfeeding in the era of biologics. Dig Liver Dis. 2013 Oct;45(10):787-94. Resumen Texto completo (enlace a fuente original) Texto completo (en nuestros servidores)
- Selinger CP, Leong RW, Lal S. Pregnancy related issues in inflammatory bowel disease: evidence base and patients' perspective. World J Gastroenterol. 2012 Resumen Texto completo (enlace a fuente original) Texto completo (en nuestros servidores)
- Habal FM, Huang VW. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. Aliment Pharmacol Ther. 2012 Resumen Texto completo (enlace a fuente original) Texto completo (en nuestros servidores)
- van der Woude CJ, Kolacek S, Dotan I, Oresland T, Vermeire S, Munkholm P, Mahadevan U, Mackillop L, Dignass A; European Crohn's Colitis Organisation (ECCO). European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis. 2010 Resumen Texto completo (enlace a fuente original) Texto completo (en nuestros servidores)
- Van Assche G, Dignass A, Reinisch W, van der Woude CJ, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart DC, D'Haens G, Gionchetti P, Portela F, Vucelic B, Söderholm J, Escher J, Koletzko S, Kolho KL, Lukas M, Mottet C, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis. 2010 Resumen Texto completo (en nuestros servidores)
- Mottet C, Vader JP, Felley C, Froehlich F, Gonvers JJ, Juillerat P, Stockbrügger R, Angelucci E, Seibold F, Michetti P, Pittet V; EPACT II Study Group. Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): Results of a multidisciplinary international expert panel-EPACT II. J Crohns Colitis. 2009 Resumen Texto completo (enlace a fuente original) Texto completo (en nuestros servidores)
- Heetun ZS, Byrnes C, Neary P, O'Morain C. Review article: Reproduction in the patient with inflammatory bowel disease. Aliment Pharmacol Ther. 2007 Resumen Texto completo (enlace a fuente original) Texto completo (en nuestros servidores)
- Mahadevan U, Kane S. American gastroenterological association institute technical review on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006 Jul;131(1):283-311. Review. Resumen Texto completo (enlace a fuente original) Texto completo (en nuestros servidores)
- Silverman DA, Ford J, Shaw I, Probert CS. Is mesalazine really safe for use in breastfeeding mothers? Gut. 2005 Resumen Texto completo (enlace a fuente original) Texto completo (en nuestros servidores)
- Sánchez-Marín B, Grasa JM. Trombosis del seno longitudinal superior en un lactante: ¿secundaria a una exposición prolongada a mesalazina? [Thrombosis of the superior sagittal sinus in an infant: secondary to prolonged exposure to mesalazine?]. Rev Neurol. 2004 Jan 16-31;38(2):200. Spanish. (No abstract) Resumen
- Kanenguiser P, Goyheneche B, Filinger E. Aminosalicilatos: Características de las Formulaciones Orales Utilizadas en el Tratamiento de la Enfermedad Inflamatoria Intestinal. Lat. Am. J. Pharm. 22 (3): 255-60 2003 Texto completo (enlace a fuente original) Texto completo (en nuestros servidores)
- Barriuso LM, Yoldi-Petri ME, Olaciregui O, Iceta-Lizarraga A, Goñi-Orayen C. Trombosis del seno longitudinal superior en un lactante: ¿secundaria a una exposición prolongada a mesalazina? [Thrombosis of the superior sagittal sinus in a breast fed infant: secondary to prolonged exposure to mesalazine?]. Rev Neurol. 2003 Jun 16-30;36(12):1142-4. Spanish. Resumen
- Moretti Myla Emily. Prospective follow-up of infants exposed to 5-aminosalicylic acid containing drugs through maternal milk. Thesis. Department of Pharmacology \ University of Toronto 1998 Resumen Texto completo (enlace a fuente original) Texto completo (en nuestros servidores)
- Connell WR. Safety of drug therapy for inflammatory bowel disease in pregnant and nursing women. Inflamm Bowel Dis. 1996 Resumen
- Christensen LA, Rasmussen SN, Hansen SH. Disposition of 5-aminosalicylic acid and N-acetyl-5-aminosalicylic acid in fetal and maternal body fluids during treatment with different 5-aminosalicylic acid preparations. Acta Obstet Gynecol Scand. 1994 May;73(5):399-402. Resumen
- Miller LG, Hopkinson JM, Motil KJ, Corboy JE, Andersson S. Disposition of olsalazine and metabolites in breast milk. J Clin Pharmacol. 1993 Resumen
- Ito S, Blajchman A, Stephenson M, Eliopoulos C, Koren G. Prospective follow-up of adverse reactions in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol. 1993 May;168(5):1393-9. Resumen
- Klotz U, Harings-Kaim A. Negligible excretion of 5-aminosalicylic acid in breast milk. Lancet. 1993 Resumen
- Jenss H, Weber P, Hartmann F. 5-Aminosalicylic acid and its metabolite in breast milk during lactation. Am J Gastroenterol. 1990 Resumen
- Nelis GF. Diarrhoea due to 5-aminosalicylic acid in breast milk. Lancet. 1989 Resumen
- Branski D, Kerem E, Gross-Kieselstein E, Hurvitz H, Litt R, Abrahamov A. Bloody diarrhea--a possible complication of sulfasalazine transferred through human breast milk. J Pediatr Gastroenterol Nutr. 1986 Mar-Apr;5(2):316-7. Resumen